Noriko Togashi

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

Naomi Shimazaki, Noriko Togashi, Masaharu Hanai et al. · European Journal of Cancer · 2008 · 62 citations

Medicine, Oncology, Pharmacology +6

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells

Tomoya Aikawa, Noriko Togashi, Koichi Iwanaga et al. · Oncotarget · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring

Ryutaro Kanada, Yoshiko Kagoshima, Masayoshi Asano et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 19 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +16

11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions

Yasuhito Nagamoto, M Miyamoto, Noriko Togashi et al. · Annals of Oncology · 2020 · 14 citations · Full text

Medicine, Oncology, Pharmacology +11